Picture loading failed.

Anti-ITGAL therapeutic antibody (Pre-made Efalizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -mab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a[1] subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-166-1mg 1mg 3090
GMP-Bios-ab-166-10mg 10mg 21890
GMP-Bios-ab-166-100mg 100mg 148000
GMP-Bios-ab-166-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ITGAL therapeutic antibody (Pre-made Efalizumab biosimilar,Whole mAb)
INN Name Efalizumab
TargetITGAL
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure3eo9:HL/3eoa:HL:BA/3eob:HL:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2001
Year Recommended2002
CompaniesGenentech;Merck Serono;XOMA
Conditions ApprovedPsoriasis
Conditions Activena
Conditions DiscontinuedPsoriatic arthritis;Type 1 diabetes mellitus
Development Techna